Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 12, 2025British Journal of HaematologyOpen Access

Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis

View Full Paper
Ask AI
Bookmark
Share

Authors

HJHuimin JinZGZhen GuoLZLìyǐng Zhū

Discussion

Loading...

Member takes

Overview

Predictive model identifies key markers predicting acute myeloid leukaemia in myelodysplastic syndrome patients, indicating improved risk stratification.

Key Points

  • This research aims to improve predictions for myelodysplastic syndromes transforming to acute myeloid leukaemia by integrating genomic and clinical data.
  • Characterized genetic and clinical features of 437 newly diagnosed MDS patients.
  • Developed a predictive model for AML transformation using bone marrow blast percentage and various mutations.
  • Established prognostic models for overall survival (OS) and progression-free survival (PFS) based on patient attributes and genetic factors.
  • Significant predictors for disease progression include bone marrow blast percentage and mutations in KRAS, STAG2, and TP53.
  • OS model incorporates age, sex, and mutations in TP53, NF1, and others, while PFS model includes similar factors with additional mutations.
  • The new models demonstrate superior risk stratification compared to existing scoring systems.

Cite This Study

Jin et al. (2025) studied this question.

synapsesocial.com/papers/6941aae10f5af7fd17df5a62https://doi.org/10.1111/bjh.70284
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognosis of the transformation of myelodysplastic syndromes to acute myeloid leukemia: A retrospective study2025 · 2 citations
  2. 2A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia2025 · 3 citations
  3. 3Distinctive Molecular Risk Factors Between <scp>MDS</scp> and <scp>MDS</scp> / <scp>AML</scp> Defined by <scp>ICC</scp>2026 · 1 citations
  4. 4Establishment and validation of a gene mutation-based risk model for predicting prognosis and therapy response in acute myeloid leukemia2024 · 3 citations
  5. 5Longitudinal genomic and cytogenetic dynamics in myelodysplastic syndromes (MDS): Insights into clonal evolution and disease progression2025